NTHI
Neonc
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NTHI
Neonc Technologies Holdings, Inc.
A biopharmaceutical company specializing in the clinical stage of developing and treating intracranial malignant tumors
2 Dole Drive, Westlake Village, CA 91362
--
Neonc Technologies Holdings, Inc., incorporated on January 5, 2023, is a Delaware corporation. As a clinical-stage biopharmaceutical company, the company has been focusing on establishing treatments for intracranial malignancies, aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, which spread through the metastasis of other cancers throughout the body, such as melanoma or breast and lung cancer. Localized malignancies of the brain are particularly difficult to treat because the blood-brain barrier prevents most drug therapies from entering the brain effectively. Therefore, these patients face the problem of poor prognosis and shortened average life expectancy. NeOnc is developing new drug delivery methods for use in combination with new drug candidates.
Company Financials
Revenue & Expenses
NTHI has released its 2024 Q4 earnings report, with revenue of 20.00K, reflecting a YoY change of NaN%, and net profit of -2.25M, showing a YoY change of 63.40%. The Sankey diagram below clearly presents NTHI’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
